Janmejay Vyas has in a short period of time diversified into multiple areas.
Dishman Pharmaceuticals and Chemicals Limited (DPCL), the company that Jay R Vyas heads, was incorporated in 1983 as a research-oriented organisation. It was originally incorporated as Dishman Pharmaceuticals and Chemicals Private Limited, a private limited company with J R Vyas as a shareholder and director.
The company was dormant until 1989 when Vyas — who holds a bachelor’s degree in chemistry from St. Xavier’s College, Ahmedabad and a bachelor’s degree in Pharma & Fine Chemical Technology from the UDCT, Mumbai — activated it and was appointed its managing director.
Ahmedabad-based Dishman Pharma, now a Rs 1,000 crore company, operates in two segments: contract research and contract manufacturing (CRAMS), and bulk drugs, intermediates, quaternary compounds and specialty chemicals. It is involved in the manufacture of active pharmaceutical ingredients (APIs), intermediates, quaternary compounds and fine chemicals.
Dishman Pharma is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. The products and services offered span customers’ needs from chemical development to commercial manufacture and supply of active pharmaceutical ingredients.
Dishman has established two wholly-owned subsidiaries — Dishman Europe Ltd. and Dishman Cyprus Ltd. Listed on the Bombay Stock Exchange (BSE), the company has five business units. Dishman Specialty Chemicals in India and China makes phase transfer catalysts, supplying high-quality intermediates, fine chemicals, and products for the pharmaceutical, cosmetics and related industries. Carbogen Amcis in Switzerland, with operations in UK and India, is a process R & D facility that supplies APIs to support clinical trial requirements.
Dishman Corporate Research and Manufacturing Services (CRAMS) in India and China provides a high-value, cost-competitive contract services facility. Dishman Vitamins & Chemicals in Netherlands and India offers Vitamin D2, Vitamin D3, Vitamin D analogues, cholesterol and lanolin-related products for the pharmaceuticals, cosmetics and related markets.
Dishman Disinfectants in India, Australiasia and Saudi Arabia on the other hand is a next-generation innovative antiseptic and disinfectant formulations unit.
“I saw the need for a company that could provide high-quality, high-value products and services and be a good and reliable partner to pharmaceutical companies worldwide,” says Vyas.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
